Need more information in your inbox? Digging for more data? A premium subscription provides both full text email alerts and access to archived news.
Support Biomarker Commons There are currently 49 users online Biomarker Commons JobsLatest Biomarker NewsSearch Biomarker NewsBiomarker News Email AlertsReach your targeted audience: advertise with us
|
fundingCvergenX, Inc. Partners with National Cancer Institute to Develop New Test to Predict Radiation Therapy SuccessA molecular signature index technology that can lead to better radiation therapy decisions for patients with cancer is being developed into a reliable radiosensitivity test by CvergenX, Inc., an advanced cancer diagnostics company. It is being done in conjunction with the National Cancer Institute’s Clinical Assay Development Program (CADP).
Tags:
One Mind for Research Receives Support from Wounded Warriors Project®One Mind for Research announced recently that Wounded Warrior Project® (WWP) has pledged $3.5 million in support of One Mind’s “Gemini Program,” contingent upon One Mind securing additional funding. “The Gemini Program” is a multi-year study of Traumatic Brain Injury (TBI) and Post-Traumatic Stress (PTS). SensiDerm™ Animal Replacement Assays Selected By Cosmetics EuropeAs of 13th March 2013, a ban was introduced in the European Union (EU) on animal testing of ingredients for cosmetics. The ban applies to all new cosmetics and their ingredients sold in the EU, regardless of where in the world testing on animals was carried out. Cosmetics Europe (formerly COLIPA), the European trade association for the cosmetic, toiletry and perfumery industry, is looking to introduce novel in-vitro assays for testing key sensitizers/allergens as a replacement for animal testing in cosmetics. Premium Subscription Required for AccessArchived news access requires a Premium Subscription. A Premium Subscription allows you and your organization full-text access to aggregated news dating back to April 2010. Need quick access? A 30-day Premium Subscription costs $49.95. Looking for a longer access option? Our annual premium subscription costs $99.95. In addition to full-text access, an Annual Premium Subscription provides an additional benefit: you'll receive the latest Biomarker Commons news stories via email in full text instead of our standard partial/excerpt text alerts. Questions? Use the contact form.
Tags:
Premium Subscription Required for AccessArchived news access requires a Premium Subscription. A Premium Subscription allows you and your organization full-text access to aggregated news dating back to April 2010. Need quick access? A 30-day Premium Subscription costs $49.95. Looking for a longer access option? Our annual premium subscription costs $99.95. In addition to full-text access, an Annual Premium Subscription provides an additional benefit: you'll receive the latest Biomarker Commons news stories via email in full text instead of our standard partial/excerpt text alerts. Questions? Use the contact form.
Tags:
Premium Subscription Required for AccessArchived news access requires a Premium Subscription. A Premium Subscription allows you and your organization full-text access to aggregated news dating back to April 2010. Need quick access? A 30-day Premium Subscription costs $49.95. Looking for a longer access option? Our annual premium subscription costs $99.95. In addition to full-text access, an Annual Premium Subscription provides an additional benefit: you'll receive the latest Biomarker Commons news stories via email in full text instead of our standard partial/excerpt text alerts. Questions? Use the contact form.
Tags:
|
